Active Ingredient History
Fludarabine or fludarabine phosphate is a chemotherapy drug used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas). It is a purine analog, which interferes with DNA synthesis. Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A), that is relatively resistant to deamination by adenosine deaminase. Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adenocarcinoma, Clear Cell (Phase 1)
Adrenal Cortex Neoplasms (Phase 1)
Agammaglobulinemia (Phase 2)
Aged (Phase 2/Phase 3)
Allergy and Immunology (Phase 2)
Allogeneic Cells (Phase 2)
Allografts (Phase 2)
Anemia (Phase 3)
Anemia, Aplastic (Phase 3)
Anemia, Diamond-Blackfan (Phase 2/Phase 3)
Anemia, Hemolytic, Autoimmune (Phase 2)
Anemia, Refractory (Phase 3)
Anemia, Sickle Cell (Phase 3)
Antigens, CD (Phase 2)
Antigens, CD19 (Phase 2)
Anus Neoplasms (Phase 2)
Arthritis, Psoriatic (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Autoimmune Diseases (Phase 2)
Autoimmune Diseases of the Nervous System (Early Phase 1)
Autoimmune Lymphoproliferative Syndrome (Phase 2)
beta-Thalassemia (Phase 4)
Biomarkers (Phase 1)
Body Weight (Phase 2)
Bone Marrow Cells (Phase 2)
Bone Marrow Failure Disorders (Phase 3)
Bone Marrow Transplantation (Phase 3)
Brain Neoplasms (Phase 1/Phase 2)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 4)
Carcinoma (Phase 1)
Carcinoma, Adenosquamous (Phase 2)
Carcinoma, Giant Cell (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma in Situ (Phase 1)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Cerebellum (Phase 2)
Cerebrospinal Fluid (Phase 1)
Cervical Intraepithelial Neoplasia (Phase 1)
Chediak-Higashi Syndrome (Phase 2/Phase 3)
Cholangiocarcinoma (Phase 2)
Chondrosarcoma (Phase 2)
Choroid Plexus Neoplasms (Phase 1)
Chromosome Aberrations (Phase 2)
Chronic Disease (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Common Variable Immunodeficiency (Phase 2)
Congenital Bone Marrow Failure Syndromes (Phase 2)
Core Binding Factors (Phase 4)
Crohn Disease (Phase 2)
Deficiency Diseases (Phase 2)
Desmoplastic Small Round Cell Tumor (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 1)
DiGeorge Syndrome (Phase 2)
Diploidy (Phase 2)
DNA Mismatch Repair (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Dyskeratosis Congenita (Phase 2/Phase 3)
Endodermal Sinus Tumor (Phase 1)
Endometrial Neoplasms (Phase 1/Phase 2)
Endoscopy (Phase 2)
Enteropathy-Associated T-Cell Lymphoma (Phase 1)
Ependymoma (Phase 1)
Epidermolysis Bullosa (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fanconi Anemia (Phase 2/Phase 3)
Fever (Phase 2)
Gallbladder Neoplasms (Phase 1/Phase 2)
Gastrointestinal Neoplasms (Phase 1/Phase 2)
GATA2 Transcription Factor (Phase 2)
Genetic Diseases, Inborn (Phase 2)
Geriatrics (Phase 2)
Giant Cell Tumor of Bone (Phase 2)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 1/Phase 2)
Gliosarcoma (Phase 1/Phase 2)
Glomerulonephritis (Phase 1)
Graft vs Host Disease (Phase 2/Phase 3)
Granulomatous Disease, Chronic (Phase 2)
Hair (Phase 3)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Hematologic Diseases (Phase 2/Phase 3)
Hematologic Neoplasms (Phase 2)
Hematology (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 3)
Hemoglobinopathies (Phase 2)
Hemoglobin SC Disease (Phase 2)
Hemoglobinuria, Paroxysmal (Phase 3)
Hepatoblastoma (Phase 1)
Histiocytosis (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2/Phase 3)
HIV (Phase 2)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 3)
Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)
Immune System Diseases (Phase 2/Phase 3)
Immunoglobulin Light-chain Amyloidosis (Phase 1/Phase 2)
Immunoglobulin M (Phase 2)
Immunologic Deficiency Syndromes (Phase 2)
Immunoproliferative Disorders (Phase 1)
Immunosuppression Therapy (Phase 2)
Infections (Phase 2)
Inflammation (Phase 2)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 2)
Kidney Neoplasms (Phase 2)
Kidney Transplantation (Phase 2)
Leukemia (Phase 4)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Erythroblastic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 2)
Leukemia, Lymphoid (Phase 4)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Mast-Cell (Phase 2)
Leukemia, Megakaryoblastic, Acute (Phase 2)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Leukemia, Myelomonocytic, Juvenile (Phase 3)
Leukemia, Neutrophilic, Chronic (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Leukemia, Prolymphocytic (Phase 3)
Leukemia, Prolymphocytic, B-Cell (Phase 2)
Leukemia, Prolymphocytic, T-Cell (Phase 3)
Leukemia, T-Cell (Phase 1)
Liposarcoma (Phase 1)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lupus Nephritis (Phase 1)
Lymphadenopathy (Phase 2)
Lymphatic Diseases (Phase 1)
Lymphocytosis (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 2/Phase 3)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 4)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 1/Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 2)
Lymphomatoid Papulosis (Phase 1)
Lymphoproliferative Disorders (Phase 4)
Mastocytosis (Phase 2)
Medulloblastoma (Phase 1)
Melanoma (Phase 3)
Melanoma, Experimental (Phase 2)
Meningioma (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 1/Phase 2)
Metabolic Diseases (Phase 2)
Metabolism (Phase 1)
Metabolism, Inborn Errors (Phase 2)
Microsatellite Instability (Phase 2)
Mucositis (Phase 3)
Multiple Myeloma (Phase 4)
Multiple Sclerosis (Phase 2)
Mutation (Phase 2)
Myasthenia Gravis (Early Phase 1)
Mycoses (Phase 2)
Mycosis Fungoides (Phase 1)
Myelodysplastic Syndromes (Phase 4)
Myeloid Cells (Phase 1)
Myeloproliferative Disorders (Phase 4)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasm, Residual (Phase 2)
Neoplasms ()
Neoplasms by Histologic Type (Phase 1/Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neoplasms, Neuroepithelial (Early Phase 1)
Neoplasms, Plasma Cell (Phase 2)
Neoplasms, Squamous Cell (Phase 2)
Nerve Sheath Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 1)
Neuroectodermal Tumors, Primitive (Phase 1)
Neuroendocrine Tumors (Phase 2)
Neurofibrosarcoma (Phase 1)
Neuromyelitis Optica (Early Phase 1)
Neutropenia (Phase 3)
Neutrophils (Phase 2)
Organ Transplantation (Phase 2)
Oropharyngeal Neoplasms (Phase 2)
Osteopetrosis (Phase 3)
Osteosarcoma (Phase 2)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pancytopenia (Phase 1/Phase 2)
Papilloma (Phase 1)
Papillomavirus Infections (Phase 1)
Paraproteinemias (Phase 2)
Pediatrics (Phase 1)
Penile Neoplasms (Phase 2)
Plasma (Phase 3)
Plasmacytoma (Phase 2)
POEMS Syndrome (Phase 1)
Polycythemia Vera (Phase 2)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Early Phase 1)
Precancerous Conditions (Phase 2)
Preleukemia (Phase 1)
Primary Immunodeficiency Diseases (Phase 2)
Primary Myelofibrosis (Phase 3)
Prostatic Neoplasms (Phase 1)
Psoriasis (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Rectal Neoplasms (Phase 2)
Recurrence (Phase 2)
Renal Insufficiency (Phase 1)
Rhabdoid Tumor (Phase 1)
Rhabdomyosarcoma (Phase 2)
Risk Factors (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Clear Cell (Phase 1)
Sarcoma, Ewing (Phase 2)
Sarcoma, Myeloid (Phase 2)
Sarcoma, Synovial (Phase 1)
Scleroderma, Systemic (Phase 3)
Sclerosis (Phase 2)
Severe Combined Immunodeficiency (Phase 2/Phase 3)
Sezary Syndrome (Phase 2)
Shwachman-Diamond Syndrome (Phase 2/Phase 3)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stem Cell Transplantation (Phase 2)
Stomach Neoplasms (Phase 2)
Sweat (Phase 2)
Synovitis (Phase 2)
Testicular Neoplasms (Phase 2)
Thalassemia (Phase 2/Phase 3)
Thrombasthenia (Phase 2)
Thrombocythemia, Essential (Phase 2)
Thrombocytopenia (Phase 2)
Thyroid Neoplasms (Phase 2)
Tissue Donors (Phase 2)
Translocation, Genetic (Phase 2)
Transplantation (Phase 3)
Triple Negative Breast Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 2)
Vasculitis (Phase 1)
Vulvar Diseases (Phase 1)
Vulvar Neoplasms (Phase 1)
Waldenstrom Macroglobulinemia (Phase 3)
Weight Loss (Phase 2)
Wilms Tumor (Phase 1)
Wiskott-Aldrich Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
